FDA Approves Belzutifan for Cancers Associated with Von Hippel-Lindau Disease
Hypoxia-inducible factor inhibitor was investigated in the ongoing Study 004
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1552 results
A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical Utility in NETs Management
The 51-gene expression-based liquid biopsy accurately diagnoses neuroendocrine tumours and is an effective surrogate marker compared to chromogranin A
FDA Approves Lenvatinib Plus Pembrolizumab for Advanced Renal Cell Carcinoma
Evidence for efficacy of combination treatment is based the results of the CLEAR study
Elucidating a Risk of Developing Second Primary Malignancy During and After Treatment with PARP Inhibitors
Findings from a systematic review and safety meta-analysis of placebo-controlled randomised controlled studies with a median follow-up ranging up to 78 months
Similar Disease-Free Survival with Extended Intermittent or Continuous Treatment with Letrozole in Breast Cancer
Findings from the SOLE and SOLE Estrogen Substudy in postmenopausal women with hormone receptor-positive, lymph node-positive, operable breast cancer
Low Dose Dexamethasone Effective as Premedication for Taxanes to Prevent Hypersensitivity Reactions
Findings from a retrospective cohort study determine no association between dose of dexamethasone and rate of hypersensitivity reactions
COVID-19 Vaccination Efficient in Patients with Cancer Who Receive Active Anticancer Treatment
Findings from an analysis of the clinical efficacy of COVID-19 vaccination in a large series of patients with cancer
ER-Low Positive Breast Cancer Shows Similar Clinical Behaviour and Response to Neoadjuvant Chemotherapy to TNBC
The use of a 10% cut-off to define oestrogen receptor positivity more appropriate than <1% to define triple-negative breast cancer
Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST
Primary endpoint of progression-free survival not met in the phase III VOYAGER study in patients with molecularly unselected gastrointestinal stromal tumour
Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated NSCLC
Findings from the CHRYSALIS study in patients with non-small cell lung cancer after progression on platinum-based chemotherapy
First Direct Comparison of Ibrutinib versus Acalabrutinib in Patients with Previously Treated CLL
Phase III study results point to noninferiority of acalabrutinib, while it provides improved safety in patients with previously treated chronic lymphocytic leukaemia
FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer
KEYNOTE-522 study was the basis for approval in the neoadjuvant and adjuvant setting